Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year High - Here's Why

Key Points

• Dianthus Therapeutics' stock reached a new **52-week high** of **$40.14** during trading, closing at **$39.59** with strong analyst support indicating a **consensus price target of $61.57**.
• The company reported a quarterly loss of **($0.88) EPS**, falling short of the expectation of **($0.86)**, with **revenue of only $0.19 million** compared to the expected **$0.87 million**.
• Insider trading activity showed CFO Ryan Savitz sold **20,000 shares** for **$700,000**, with **16.56% of the stock** currently owned by insiders.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $40.14 and last traded at $39.59, with a volume of 14699 shares traded. The stock had previously closed at $39.55.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on DNTH shares. William Blair started coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an "outperform" rating on the stock. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, September 8th. Guggenheim boosted their target price on Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, September 9th. Wedbush raised their price target on Dianthus Therapeutics from $42.00 to $44.00 and gave the company an "outperform" rating in a report on Friday, September 12th. Finally, Raymond James Financial reiterated an "outperform" rating and set a $63.00 target price (up from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday, September 9th. Nine analysts have rated the stock with a Buy rating, According to MarketBeat, Dianthus Therapeutics currently has an average rating of "Buy" and a consensus price target of $61.57.

Dianthus Therapeutics Stock Up 0.2%

The company's 50 day moving average price is $26.92 and its two-hundred day moving average price is $21.72. The firm has a market cap of $1.28 billion, a PE ratio of -12.13 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. On average, analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the company's stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 16.56% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. ADAR1 Capital Management LLC increased its holdings in Dianthus Therapeutics by 3.4% during the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company's stock valued at $332,000 after buying an additional 602 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock worth $280,000 after acquiring an additional 618 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Dianthus Therapeutics by 1.0% in the 1st quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company's stock worth $1,336,000 after buying an additional 748 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Dianthus Therapeutics by 0.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company's stock valued at $3,049,000 after purchasing an additional 1,081 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics during the second quarter valued at approximately $27,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.